ATC Group: A04AD12 Aprepitant

Anatomical Therapeutic Chemical Classification System

Hierarchical position in ATC classification

Level
Code
Title
1
Alimentary tract and metabolism
2
Antiemetics and antinauseants
3
Antiemetics and antinauseants
4
Other antiemetics
5
A04AD12
Aprepitant

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
95 mg
PAREN - Parenteral
95 mg

Active ingredients

Active Ingredient
Description

Aprepitant is a selective high-affinity antagonist at human substance P neurokinin 1 (NK1) receptors.

Fosaprepitant is the prodrug of aprepitant and when administered intravenously is converted rapidly to aprepitant. The contribution of fosaprepitant to the overall antiemetic effect has not fully been characterised, but a transient contribution during the initial phase cannot be ruled out.

Medicines in this ATC group

Drug
Countries

South Africa

Austria

Austria Brazil Canada Cyprus Estonia ...

Australia Brazil Canada Hong Kong Singapore ...

South Africa

Brazil

South Africa

Austria Canada Estonia Finland Ireland ...

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)
Structured Product Monograph (SPM)
CA
Summary of Product Characteristics (SPC)